COTA Healthcare

Name

COTA Healthcare

Legal name

COTA, Inc.

Website

https://cotahealthcare.com

Company type

Private

Founded year

2011

Operating status

Acquired

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Oncology Real-World Data Analytics

NAICS

Scientific Research and Development Services (5417), Software Publishers (5132)

SIC

Services-Health Services (8000)

akta.pro primary industry

Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF)

akta.pro secondary industries

Data Linkage, Registries & Longitudinal Cohort Surveillance (HLAJANAM), Oncology Pathways & Precision Medicine Decision Support (HLACAGAH)

Keywords

• Oncology real-world data
• Real-world evidence platform
• Clinical data curation
• Oncology analytics software
• Clinicogenomic datasets

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Real-World Data Subscriptions and Licensing: COTA provides curated oncology real-world datasets to life sciences companies through subscription and licensing arrangements. These include regulatory-grade datasets for clinical trials, HEOR support, commercial assessments, and external comparator controls.
2. Data Analytics and Research Services: Expert clinical insights, study design support, and statistical analysis services provided alongside datasets to help sponsors and investigators tailor datasets to specific protocols or regulatory requirements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

COTA Healthcare curates and licenses oncology-specific real-world datasets and analytics to life sciences companies and oncology providers. Its products (Focus, Vantage, Vista, Clinicogenomics, Real-World Analytics) deliver regulatory-grade longitudinal patient data covering 2M+ cancer patients across hematologic and solid tumor cancers, balanced 50/50 between academic and community settings. The company pairs these datasets with Real-World Insights & Support services—clinical expertise, study design, and statistical analysis—to support drug development, regulatory submissions, and external comparator arms.

Product overview

COTA Healthcare provides an oncology-focused real-world data platform with multiple database tiers (Focus, Vantage, Vista) that can be enhanced with Clinicogenomics integration. The company offers a curated database of 2M+ cancer patient lives across 50/50 academic and community settings. Focus provides small, regulatory-grade, customizable datasets with programmatic and manual curation; Vantage offers large cancer-specific datasets with standard curation; Vista provides the largest pan-cancer research-grade database. All products can access Real-World Insights & Support services including clinical insights, study design, and statistical analysis. The platform supports R&D, regulatory, commercial, and HEOR teams across the drug lifecycle.

Differentiator

Problem solved

Functional benefit

Brands

• CAILIN: AI-powered curation engine developed by COTA for transforming fragmented healthcare data into actionable insights.
• Focus
• Vantage
• Vista
• Clinicogenomics

Products and services

• Focus Focus is COTA's small, highly targeted, regulatory-grade oncology database product designed for research and development teams. It supports customizable solutions with both programmatic and manual curation and can be enhanced with clinicogenomics data for precision research.
• Vantage Vantage is COTA's large, cancer-specific database with standard curation quality, covering multiple myeloma, NSCLC, AML, and other cancer-specific datasets. It is also available through the Aetion Evidence Platform for streamlined oncology research access.
• Vista Vista is COTA's largest pan-cancer research-grade database, using programmatic-only curation to support broad population research across multiple cancer types.
• Clinicogenomics Clinicogenomics integrates COTA's longitudinal clinical oncology real-world data with patient-level genomic test results, including DNA and RNA profiling, to provide precise insights into disease origins and therapeutic interactions for precision oncology research.
• Real-World Analytics Real-World Analytics is COTA's curated database platform providing oncology patient data across 2M+ patients, with a 50/50 academic versus community treatment-settings balance, covering hematologic and solid tumor cancers including multiple myeloma, AML, DLBCL, and NSCLC.
• Real-World Insights & Support Real-World Insights & Support provides expert clinical insights, study design support, and statistical analysis services that complement COTA's curated datasets, helping life sciences sponsors and investigators tailor datasets to specific protocols or regulatory requirements.

Quantifiable outcome

• Up to 90% of clinical drug development fails; RWD can help curb failure rates by enabling better hypothesis generation and subpopulation identification
• +2 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability9 records

Feature3 records

Partnerships

Twelve partnerships are on record, tiered core and major.

• Verana HealthcoreStrategic or Co-development Partner · 13 January 2026Verana Health acquired COTA Healthcare in a $52M equity deal. The merger created a combined entity serving 17 of the top 20 global biopharma companies with access to over 95 million patients and more than 20,000 clinicians. The acquisition expanded Verana's therapeutic knowledge base, particularly in oncology.
• Guardant HealthcoreStrategic or Co-development Partner · 1 January 2025Partnership to advance precision oncology research and therapy development with real-world clinicogenomic data and AI analytics. Combines COTA's EHR data from academic and community care centers with Guardant's clinicogenomic data.
• Panalgo (Norstella)majorTechnology or Integration · 9 September 2024Partnership adding COTA's hematologic oncology data to Panalgo's Instant Health Data (IHD) platform. COTA joins Panalgo's Partner Network as their first oncology partner specializing in hematologic cancers.
• Precision Health Informatics (PHI) / Texas OncologycoreStrategic or Co-development Partner · 17 July 2024Innovative collaboration to advance AI-enabled precision medicine across Texas Oncology's community cancer centers. Leverages COTA's CAILIN AI curation engine to transform fragmented EHR data into actionable insights.
• AetioncoreTechnology or Integration · 15 November 2023Partnership to expand access to real-world data for oncology research. COTA's oncology Vantage RWD assets are available through the Aetion Evidence Platform (AEP), enabling streamlined access to fit-for-purpose datasets for research.
• Baptist Health Miami Cancer InstitutemajorStrategic or Co-development Partner · 6 April 2023Expanded partnership providing physicians with real-world evidence for cancer care. Miami Cancer Institute used COTA's analysis to change breast cancer gene mutation testing policy, demonstrating RWE impact on clinical decision-making.
• Genomic Testing Cooperative (GTC)coreStrategic or Co-development Partner · 8 March 2023Strategic partnership integrating COTA's deep clinical oncology real-world data with GTC's comprehensive genomics testing data including DNA and RNA profiling. This multi-modal partnership supports precision oncology research by combining clinical and molecular data.
• Clinical Research Data Sharing Alliance (CRDSA)majorStrategic or Co-development Partner · 31 January 2023COTA joined CRDSA, a cross-industry alliance of biopharma companies, data sharing platforms, academic institutions, and service/technology partners. COTA participates in the steering committee and Innovative Trial Design Working Group, focusing initially on NSCLC.
• Komodo HealthmajorTechnology or IntegrationPartnership combining COTA's high-quality oncology data with Komodo's vast Healthcare Map to link real-world datasets for better patient insights and comprehensive evidence generation.
• PreciseDxmajorStrategic or Co-development PartnerCollaboration with PreciseDx and Baptist Health South Florida to assess and validate the AI-enabled PreciseBreast test for breast cancer recurrence risk assessment.
• Memorial Sloan Kettering Cancer CentercoreStrategic or Co-development PartnerResearch collaboration on Diffuse Large B-Cell Lymphoma (DLBCL) studies in older patients. Research presented at ASH 2024 explored treatment urgency and end-of-life care patterns, demonstrating RWD's ability to improve cancer care plans for elderly populations.
• Georgetown Lombardi Comprehensive Cancer Center / MedStar HealthmajorStrategic or Co-development PartnerResearch partnership investigating alternative dosing schedules for colorectal and pancreatic cancer therapy using COTA's real-world data. Findings presented at ASCO GI Cancers Symposium.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Flatiron Health: Acquired by Roche, Flatiron is a leading oncology-focused real-world data and EHR analytics platform serving biopharma, regulators, and providers. It is the most direct head-to-head competitor to COTA in oncology RWD and external comparator use cases.
• Tempus Labs: Tempus combines multi-omic profiling (DNA/RNA) with an AI-enabled oncology data library sold to biopharma for R&D and clinical decision support. Highly comparable to COTA's clinicogenomics and oncology RWD offering, with a broader multi-omic footprint.
• ConcertAI: ConcertAI is an oncology-focused RWD and AI analytics company serving biopharma across clinical development, HEOR, and commercialization. Competes directly with COTA in oncology real-world evidence and external comparator studies.
• Verana Health: Verana Health is a real-world evidence company that acquired COTA in January 2026, specializing in neurology, ophthalmology, and now oncology data sourced from specialty medical societies. Former direct peer that is now COTA's parent.
• Komodo Health: Komodo Health maintains a large healthcare map and patient-level RWD platform used by biopharma for commercial and clinical analytics. COTA has a partnership with Komodo linking oncology data into Komodo's map, but Komodo is also a broader competitor.

Broad incumbents

• IQVIA: IQVIA is the largest life sciences services and real-world evidence incumbent, offering broad oncology RWD alongside its CRO, HEOR, and commercial analytics businesses. COTA's enterprise sales motion overlaps with IQVIA's RWE go-to-market.
• Foundation Medicine: Owned by Roche, Foundation Medicine provides genomic profiling and clinicogenomic datasets widely used in oncology R&D and clinical decision support. Comparable to COTA's clinicogenomics product, particularly for biopharma biomarker-driven development.

Emerging players

• Aetion: Aetion offers an RWE analytics platform used by biopharma and regulators, with which COTA has a distribution partnership making COTA's oncology data available on Aetion's Evidence Platform. Indirect competitor in RWE-enabled regulatory submissions.
• Panalgo (Norstella): Panalgo provides the Instant Health Data (IHD) analytics platform widely used for RWE studies, and integrates COTA's hematologic oncology data. Competes with COTA for the same RWE analytics buyer in biopharma HEOR and clinical teams.
• TriNetX: TriNetX operates a global health research network aggregating EHR data from hospitals for clinical trial design, protocol optimization, and real-world studies. Comparable to COTA's provider-facing EHR curation value proposition in clinical research enablement.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubepodcasts.apple.com/us/podcast/real-world-talk-with-cota/id1536949798
• LinkedInlinkedin.com/company/cotainc
• Xx.com/cotahealthcare

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds8 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about COTA Healthcare